NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Published Online: 2019-08-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alessandro Gronchi•Alexander J Lazar•Aneta Borkowska•Angel Montero•Angela Hong•Ann Co•Anne Ducassou•Antonio Casado Herraez•Augustin Mervoyer•Axel Le Cesne•Béatrice Tiangco•Cécile Le Péchoux•Esma Saada-Bouzid•Eva Wardelmann•Gabriel Kacso•Guy Kantor•Herbert H Loong•Judith V M G Bovée•Juliette Thariat•Laurence Moureau-Zabotto•Lore Lapeire•Lyn Austen•László Mangel•Marco Rastrelli•Marie-Pierre Sunyach•Michael Gebhart•Peter Agoston•Peter Hohenberger•Philippe Terrier•Piotr L Rutkowski•Ramona Vergés•Rodica Anghel•Rubi K Li•Sorin Dema•Sylvie Bonvalot•Sylvie Helfre•Sébastien Carrère•Teresa Sy-Ortin•Thierry de Baère•Victor Moreno•Vincent Servois•Zsusanna Papai
